315 related articles for article (PubMed ID: 32964391)
1. Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma.
Cho N; Ko S; Shokeen M
Mol Imaging Biol; 2021 Apr; 23(2):186-195. PubMed ID: 32964391
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Development of CD38-Targeted [
Ghai A; Maji D; Cho N; Chanswangphuwana C; Rettig M; Shen D; DiPersio J; Akers W; Dehdashti F; Achilefu S; Vij R; Shokeen M
J Nucl Med; 2018 Feb; 59(2):216-222. PubMed ID: 29025987
[TBL] [Abstract][Full Text] [Related]
3.
Quelven I; Monteil J; Sage M; Saidi A; Mounier J; Bayout A; Garrier J; Cogne M; Durand-Panteix S
J Nucl Med; 2020 Jul; 61(7):1058-1065. PubMed ID: 31862796
[TBL] [Abstract][Full Text] [Related]
4. Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma.
Cho N; Ko S; Shokeen M
Oncotarget; 2021 Sep; 12(20):2039-2050. PubMed ID: 34611478
[TBL] [Abstract][Full Text] [Related]
5. ImmunoPET imaging of CD38 in murine lymphoma models using
Kang L; Jiang D; England CG; Barnhart TE; Yu B; Rosenkrans ZT; Wang R; Engle JW; Xu X; Huang P; Cai W
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1372-1381. PubMed ID: 29450576
[TBL] [Abstract][Full Text] [Related]
6. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.
Naeimi Kararoudi M; Nagai Y; Elmas E; de Souza Fernandes Pereira M; Ali SA; Imus PH; Wethington D; Borrello IM; Lee DA; Ghiaur G
Blood; 2020 Nov; 136(21):2416-2427. PubMed ID: 32603414
[TBL] [Abstract][Full Text] [Related]
7. CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.
Ulaner GA; Sobol NB; O'Donoghue JA; Kirov AS; Riedl CC; Min R; Smith E; Carter LM; Lyashchenko SK; Lewis JS; Landgren CO
Radiology; 2020 Jun; 295(3):606-615. PubMed ID: 32255416
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma.
Stocker N; Gaugler B; Ricard L; de Vassoigne F; Marjanovic Z; Mohty M; Malard F
Cancer Med; 2020 Mar; 9(6):2077-2084. PubMed ID: 31991058
[TBL] [Abstract][Full Text] [Related]
9. CD38-specific nanobodies allow
Pape LJ; Hambach J; Gebhardt AJ; Rissiek B; Stähler T; Tode N; Khan C; Weisel K; Adam G; Koch-Nolte F; Bannas P
Front Immunol; 2022; 13():1010270. PubMed ID: 36389758
[TBL] [Abstract][Full Text] [Related]
10. BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression.
Xing L; Wang S; Liu J; Yu T; Chen H; Wen K; Li Y; Lin L; Hsieh PA; Cho SF; An G; Qiu L; Kinneer K; Munshi N; Anderson KC; Tai YT
Clin Cancer Res; 2021 Oct; 27(19):5376-5388. PubMed ID: 34301753
[TBL] [Abstract][Full Text] [Related]
11.
Shi L; Chen B; Liu T; Li L; Hu B; Li C; Jia B; Wang F
Mol Pharm; 2022 Jul; 19(7):2583-2594. PubMed ID: 35696536
[TBL] [Abstract][Full Text] [Related]
12. High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.
Clara JA; Levy ER; Reger R; Barisic S; Chen L; Cherkasova E; Chakraborty M; Allan DSJ; Childs R
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135865
[TBL] [Abstract][Full Text] [Related]
13. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.
Ogiya D; Liu J; Ohguchi H; Kurata K; Samur MK; Tai YT; Adamia S; Ando K; Hideshima T; Anderson KC
Blood; 2020 Nov; 136(20):2334-2345. PubMed ID: 32844992
[TBL] [Abstract][Full Text] [Related]
14. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Kassem S; Diallo BK; El-Murr N; Carrié N; Tang A; Fournier A; Bonnevaux H; Nicolazzi C; Cuisinier M; Arnould I; Sidhu SS; Corre J; Avet-Loiseau H; Teillaud JL; van de Velde H; Wiederschain D; Chiron M; Martinet L; Virone-Oddos A
Blood; 2022 Feb; 139(8):1160-1176. PubMed ID: 35201323
[TBL] [Abstract][Full Text] [Related]
15. A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma.
Duray E; Lejeune M; Baron F; Beguin Y; Devoogdt N; Krasniqi A; Lauwers Y; Zhao YJ; D'Huyvetter M; Dumoulin M; Caers J
J Hematol Oncol; 2021 Nov; 14(1):183. PubMed ID: 34727950
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.
Viola D; Dona A; Caserta E; Troadec E; Besi F; McDonald T; Ghoda L; Gunes EG; Sanchez JF; Khalife J; Martella M; Karanes C; Htut M; Wang X; Rosenzweig M; Chowdhury A; Sborov D; Miles RR; Yazaki PJ; Ebner T; Hofmeister CC; Forman SJ; Rosen ST; Marcucci G; Shively J; Keats JJ; Krishnan A; Pichiorri F
Leukemia; 2021 Jan; 35(1):189-200. PubMed ID: 32296125
[TBL] [Abstract][Full Text] [Related]
17. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.
Overdijk MB; Verploegen S; Bögels M; van Egmond M; Lammerts van Bueren JJ; Mutis T; Groen RW; Breij E; Martens AC; Bleeker WK; Parren PW
MAbs; 2015; 7(2):311-21. PubMed ID: 25760767
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
[TBL] [Abstract][Full Text] [Related]
19. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
20. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.
Zamagni E; Tacchetti P; Pantani L; Cavo M
Expert Rev Hematol; 2018 May; 11(5):423-435. PubMed ID: 29582696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
